Loading
A phase 1/2 trial of Rondecabtagene autoleucel, Fludarabine, Cyclophosphamide in hodgkin lymphoma and non-hodgkin lymphoma, run by Lyell Immunopharma, Inc., now recruiting.
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma is a phase 1/2 interventional study registered as NCT05826535 by Lyell Immunopharma, Inc., with 270 participants planned, started 2023-05-09 and due to reach its primary completion in 2028-12-31. Interventions recorded: Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide. Conditions listed: Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rondecabtagene autoleucel, Lyell Immunopharma, Hodgkin lymphoma.
Shares Fludarabine, Cyclophosphamide, Non-Hodgkin lymphoma (all types).
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/